Evidence map›Paper›PMID 10490761›Full record

ArticleGene therapy1999

Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers.

H Fechner, A Haack, H Wang, X Wang, K Eizema, M Pauschinger, R Schoemaker, R Veghel, A Houtsmuller, H P Schultheiss and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 309 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Concepts in Oncolytic Adenovirus Therapy.International journal of molecular sciences · 2021
    Review
  7. Review
  8. Adenovirus-MediatedInternational journal of molecular sciences · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2014
    Article
  18. Article
  19. Article
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

H FechnerDepartment of Cardiology and Pneumology, University Hospital Benjamin Franklin, Freie Universität, Berlin, Germany.
A Haack
H Wang
X Wang
K Eizema
M Pauschinger
R Schoemaker
R Veghel
A Houtsmuller
H P Schultheiss
J Lamers
W Poller
Freie Universität Berlin · DEErasmus University Rotterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant adenoviral vectors are broadly applied in gene therapy protocols. However, adenovector-mediated gene transfer has limitations in vivo. One of these is the low gene transfer rate into organs other than the liver after systemic intravenous vector injection. Local direct injection into the target organ has been used as one possible solution, but increases necessary equipment and methodology and is traumatic to the target. Wild-type adenovirus infection as well as adenovector-mediated gene transfer depends on virus interaction with the Coxsackie adenovirus receptor (CAR) mediating virus attachment to the cell surface, and on interaction with alphavbeta3 and alphavbeta5 integrins mediating virus entry into the cell. In order to assess the receptor-associated potential of different tissues to act as adenovector targets, we have therefore determined CAR and alphav-integrin expression in multiple organs from different species. In addition, we have newly determined several human, rat, pig and dog CAR-mRNA sequences. Sequence comparison and structural analyses of known and of newly determined sequences suggests a potential adenovirus binding site between amino acids 29 and 128 of the CAR. With respect to the virus receptor expression patterns we found that CAR-mRNA expression was extremely variable between different tissues, with the highest levels in the liver, whereas alphav-integrin expression was far more homogenous among different organs. Both CAR and alphav-integrin showed similar expression patterns among different species. There was no correlation, however, between the adenovector expression patterns after intravenous, intracardiac and aortic root injection, respectively, and the virus receptor patterns. In summary, many organs carry both receptors required to make them potential adenovector targets. In sharp contrast, their actual targeting clearly indicates that adenovirus receptor expression is necessary but not sufficient for vector transfer after systemic injection. The apparently very important role of anatomical barriers, in particular the endothelium, requires close attention when developing non-traumatic, organ-specific gene therapy protocols.

Indexed as

Gene Transfer TechniquesReceptors, VirusAdenoviridaeAnimalsAntigens, CDBlotting, NorthernCoxsackie and Adenovirus Receptor-Like Membrane ProteinDogsEndotheliumGene ExpressionGenetic TherapyGenetic VectorsGreen Fluorescent ProteinsHumansIntegrin alpha5KidneyAntigens, CDCLMP protein, humanCLMP protein, mouseClmp protein, ratCoxsackie and Adenovirus Receptor-Like Membrane ProteinGreen Fluorescent ProteinsIntegrin alpha5LuciferasesLuminescent ProteinsReceptors, VirusRNA, Messenger

Identifiers

PMID10490761
OpenAlexW2035834158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.